Avidity Biosciences Inc
RNA
$25.09
Closing
▼-0.20%
1D
▲177.24%
YTD
Market cap
$2.38B
52 week high
$27.64
52 week low
$4.84
Volume
229,859
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$2.38B
Analysts' Rating
BUY
Price Target (Mean)
36.16667
Total Analysts
6
P/E
Operating Margin
-2080.38%
Beta
0.77
Revenue Growth (Annual)
-1.09%
52 week high
$27.64
52 week low
$4.84
Div. Yield
%
EPS Annual Growth
7.58
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs.). The Company’s AOC platform is designed to combine the specificity of monoclonal antibodies (mAbs), with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with RNA therapeutics. The AOC platform also has the option to deploy various types of oligonucleotides, including small interfering RNA (siRNAs) and patient measure of safety (PMOs), whose specific mechanisms of action modify RNA function in different ways. The Company’s pipeline includes AOC 1001, and AOC 1020. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1). AOC 1020 is designed to treat people living with facioscapulohumeral.
